How do I choose between different specialty pharma CROs for a biomarker-driven rare disease program?

Choosing a specialty pharma CRO for a biomarker-driven rare disease program is less about picking the “biggest” vendor and more about finding the CRO that can de-risk a very specific scientific and operational path.

Here’s a practical way to choose.

1) Start with the program’s real risks

For rare disease biomarker programs, the key risks are usually:

• Patient identification / recruitment
• Biomarker assay validity and turnaround time
• Natural history / endpoint selection
• Site feasibility across very small patient pools
• Regulatory strategy for companion biomarker evidence
• Data integration across central labs, imaging, genomics, and ePRO
• Operational flexibility when protocol assumptions prove wrong

Pick a CRO based on which of those are most critical in your study.

2) Prioritize domain fit over general CRO reputation

A specialty pharma CRO should have experience in:

• Rare disease trial design
• Biomarker-enriched or biomarker-stratified studies
• Central lab and translational science workflows
• Assay management / sample logistics
• Adaptive designs, small-N statistics, or master protocols
• Global site networks for ultra-rare populations
• Regulatory interactions involving biomarkers and precision medicine

Ask for examples in the same therapeutic area or at least the same biomarker modality:

• Genomic / NGS
• Proteomic
• Metabolomic
• Circulating biomarkers
• Imaging biomarkers
• Digital biomarkers

3) Evaluate their biomarker operations deeply

This is often the differentiator.

Questions to ask:

• Do they manage sample chain of custody and pre-analytics robustly?
• Do they have experience with fit-for-purpose assay validation?
• Can they support central lab, specialty lab, and translational lab coordination?
• How do they handle turnaround time for screening biomarkers?
• What is their process when an assay fails, changes, or needs bridging?
• Do they have experience with evidence packages for regulatory submissions?

If the biomarker is central to enrollment or endpoint success, you want a CRO that can run the biomarker workflow, not just “coordinate with the lab.”

4) Assess rare disease patient access capability

In rare disease, execution often depends on network strength more than headcount.

Look for:

• Established relationships with patient advocacy groups
• Ability to work with specialist referral centers
• Global reach into regions where patients actually exist
• Realistic site activation timelines
• Access to medical science liaisons and disease-area KOLs
• Experience with decentralized or hybrid trial elements

Ask them:

• “How many patients with this phenotype have you enrolled in the last 2–3 years?”
• “What’s your plan if the expected patient count is overestimated by 30–50%?”

5) Look for statistical and design sophistication

Biomarker-driven rare disease studies often fail because the design is too rigid.

You want a CRO that can support:

• Small sample size and Bayesian methods
• Enrichment strategies
• Adaptive interim analyses
• Natural history comparators / external controls
• Endpoint refinement with limited prior evidence
• Multiplicity control when biomarkers and clinical endpoints interact

If the CRO doesn’t have strong biostats that understand rare disease, that’s a red flag.

6) Check regulatory and medical writing strength

You need a CRO that can help shape the story, not just collect data.

Evaluate:

• Experience with FDA/EMA rare disease and biomarker meetings
• Ability to support protocol justification for novel endpoints
• Knowledge of orphan drug / expedited pathways
• Medical writing quality for:
  • Protocols
  • IBs
  • SAPs
  • Clinical study reports
  • Regulatory briefing docs

7) Examine operational responsiveness and governance

Specialty pharma programs move fast and change often.

Compare CROs on:

• Senior team involvement
• Decision-making speed
• Escalation paths
• Sponsor access to functional leads
• Transparency in issue management
• Ability to scale up/down without losing continuity

A small expert CRO can outperform a large one if the communication and accountability are better.

8) Understand their vendor ecosystem

Biomarker programs depend on multiple vendors:

• Central lab
• Specialty assay lab
• Imaging core lab
• eCOA/ePRO vendor
• Biobanking / sample logistics
• Data platform / biostats support

Choose a CRO that can integrate these vendors smoothly or has a proven model for managing them. Fragmented vendor oversight is a common source of delays.

9) Compare them on concrete deliverables, not slide decks

Ask each CRO to provide:

• A program-specific operational strategy
• A risk register
• A recruitment feasibility assessment
• A biomarker workflow map
• A sample timeline from first patient in to database lock
• Example KPIs / metrics
• A proposed governance model

Then compare how specific, realistic, and evidence-based the responses are.

10) Red flags

Be cautious if a CRO:

• Claims broad biomarker expertise but gives vague examples
• Has no real rare disease recruitment strategy
• Treats the biomarker as a “lab add-on” rather than core program infrastructure
• Overpromises enrollment in an ultra-rare population
• Lacks strong data integration and assay governance
• Can’t explain how they handle protocol amendments and assay changes
• Has little experience with external controls or novel endpoints

A simple scorecard you can use

Rate each CRO from 1–5 on:

• Rare disease therapeutic expertise
• Biomarker assay/workflow expertise
• Site and patient access
• Study design and biostatistics
• Regulatory experience
• Data integration / vendor management
• Communication and governance
• Cost/value
• Flexibility
• Track record in similar programs

Then weight the categories based on what matters most to your study. For many biomarker-driven rare disease programs, the top weights are:

1. Biomarker operations
2. Patient access
3. Study design/biostatistics
4. Regulatory expertise

Bottom line

For a biomarker-driven rare disease program, choose the CRO that best combines:

• Disease-specific credibility
• Biomarker operational rigor
• Rare patient access
• Smart study design
• Regulatory fluency

If you want, I can also give you:

1. a vendor selection scorecard template,
2. a CRO RFP question list, or
3. a side-by-side evaluation matrix you can use with actual CRO proposals.